Strong Buy Rating for Dynavax Amidst Promising Growth and Market Prospects

Dynavax (DVAX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Phil Nadeau from TD Cowen maintained a Buy rating on the stock and has a $25.00 price target.

Phil Nadeau has given his Buy rating due to a combination of factors related to Dynavax’s performance and future prospects. Despite Heplisav’s Q1 revenue of $65 million falling short of the $70 million consensus, it was still the best first quarter for Heplisav, showing a 36% year-over-year growth. This growth, coupled with management’s expectation for 2025 revenue to reach the upper end of the $305 million to $325 million guidance, suggests a strong market position for Heplisav.
Furthermore, Dynavax is poised to benefit from the expanding U.S. adult HBV vaccine market, anticipated to exceed $900 million by 2030. The company expects Heplisav to capture a majority market share by 2027 and at least 60% by 2030, driven by factors such as the ACIP recommendation and increasing market penetration. Additionally, upcoming data from the Phase I/II trial of Z-1018, expected in Q3 2025, adds to the potential upside, reinforcing the Buy rating.

According to TipRanks, Nadeau is a 3-star analyst with an average return of 1.2% and a 40.63% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Biogen, and Neurocrine.